Idiopathic hypersomnia treatment should be determined based on factors like symptom profile, age, comorbidities, and additional medications, says review. Treatments to manage idiopathic hypersomnia ...

LUMRYZ is only currently approved for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy, and Avadel does not market, promote or offer patient support services ...

Sleep is essential for a person’s health, and people who feel tired on occasion often boost their energy levels by taking a nap or ensuring restful shut-eye the next evening. But when sleep doesn't ...

Beacon Biosignals, a leader in AI-driven neurophysiology and precision drug development, today announced a collaboration with Harmony Biosciences (Nasdaq: HRMY), a pharmaceutical company dedicated to ...

Avadel Pharmaceuticals announced that its drug LUMRYZTM received Orphan Drug Designation from the FDA for treating Idiopathic Hypersomnia (IH), a rare sleep disorder. This designation, based on the ...

Tired man sitting at desk in modern office Serdexmethylphenidate is a proprietary prodrug of d-methylphenidate. The Food and Drug Administration (FDA) has granted Orphan Drug designation to ...

Michael Thorpy, MD, professor of neurology, Albert Einstein College of Medicine explores the current treatment landscape of idiopathic hypersomnia and the associated challenges with approving new ...

Avadel Pharmaceuticals (AVDL) announced the completion of patient enrollment in REVITALYZ, a Phase 3 trial evaluating LUMRYZTM extended-release oral suspension as a potential treatment for idiopathic ...

Being tired throughout the day is a common feeling for most individuals. In fact, 1 out of every 5 Americans see a doctor with complaints of daytime sleepiness. However, for some individuals, daytime ...

Please provide your email address to receive an email when new articles are posted on . INDIANAPOLIS — Treatment with Xywav was effective in addressing symptoms of idiopathic hypersomnia, regardless ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted orphan drug exclusivity for JZP258, an oral low-sodium oxybate solution for the treatment of ...

Credit: Getty Images. Pitolisant is a selective histamine-3 receptor antagonist/inverse agonist. The Food and Drug Administration (FDA) has granted Orphan Drug designation to pitolisant for the ...